Efficacy and safety of Hydroxychloroquine 300 mg as an add-on triple Drug in the Treatment of Type 2 Diabetes Mellitus Uncontrolled on Metformin and Glimepiride.

Dr Nihar Ranjan Bhattacharya0 个研究点目标入组 30 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•Patients diagnosed of uncontrolled type 2 diabetes who are receiving treatment with OAD metformin 1000 mg/day and glimepiride 2mg/day are on stable dose for at least 12 weeks.
•Patients with HbA1c >=7.0 % and <=9 %.
•Patients with body weight >=60 kg.
•Patients able to understand and willing to fully comply with study procedures and restrictions.

•Uncontrolled hyperglycemia i.e. FPG >240 mg/dL.
•Patients with a history or presence of any retinopathy of any grade including diabetic retinopathy requiring laser therapy, evidence of an imminent need for retinal laser therapy, uncorrected visual acuity <20/100, abnormal visual fields, difficulty to examine optic disc, or evidence of retinal pigment epithelial abnormalities and patients with history or risk of macular edema.
•Patients with recent ( <1 year) CV events i.e. myocardial infarction/ACS, stroke or has undergone coronary artery bypass surgery, percutaneous transluminal coronary angioplasty or transient ischemic attack, or history of congestive heart failure, or unstable angina.
•Patient with known history of diabetic ketoacidosis Glucose-6-phophodehydrogenase deficiency Known allergy to the substance, and breastfeeding.

发起方

Dr Nihar Ranjan Bhattacharya